FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely endocrinology, and concerns treating type 1 diabetes. That is ensured by administering a combination consisting of a dipeptidyl peptidase-4 inhibitor (DPP-4), a proton pump inhibitor (PPI) and gamma-aminobutyric acid or a gamma aminobutyric acid receptor agonist.
EFFECT: such combination of drugs provides effective treatment of type 1 diabetes by regenerating beta-cells of the pancreas.
1 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH GPR119 AGONISTS AND DPP-4 INHIBITORS | 2020 |
|
RU2818562C2 |
| DIPEPTIDYL PEPTIDASE-4 INHIBITOR FOR TREATMENT OF TYPE 2 DIABETES | 2015 |
|
RU2628573C2 |
| DRUG FOR PREVENTION AND TREATMENT OF DIABETES | 2013 |
|
RU2597848C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| HYPOGLYCEMIC AGENT OF PEPTIDE STRUCTURE INHIBITING DIPEPTIDYL PEPTIDASE-4 | 2015 |
|
RU2600810C1 |
| DIPEPTIDYL PEPTIDASE IV INHIBITING AGENT AND PHARMACEUTICAL COMPOSITION THEREOF | 2011 |
|
RU2485952C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| AGENT OF PEPTIDE STRUCTURE, INHIBITING DIPEPTIDYL PEPTIDASE-4, AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2015 |
|
RU2589258C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2732703C2 |
| AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
